Why Become a Member?
Yale Cancer Center is one of only 49 Comprehensive Cancer Centers nationwide designated by the National Cancer Institute. Throughout the fight against cancer, Yale has been at the forefront of understanding the mechanisms of cancer biology and in developing effective therapies for cancer treatment. Yale Cancer Center unites the membership to advance cancer research, prevention, and patient care, as well as community outreach and education by harnessing the resources of the Yale School of Medicine and Smilow Cancer Hospital. (Download Application)
Benefits of Membership
Member ExpectationsWhile YCC Membership has many valuable privileges, there are also important obligations. These include:
Membership Categories and CriteriaThere are three types of YCC Membership, Full, Clinical, and Research. Full Members are eligible to apply for Pilot funding, whereas Clinical and Research Members must submit with a Full Member as co-PI.
Full members have an independent Yale faculty appointment, contribute to the peer-reviewed cancer literature, and also have one of the following: 1) Obtained extramural cancer-relevant peer-reviewed grant support as a PI or Co-PI within the past 3 years; 2) Served as investigator or co-investigator on at least one YCC interventional (therapeutic or non-therapeutic) cancer clinical trial within the past 2 years; or 3) Provide specialized medical, scientific, or administrative expertise to the overall research mission of YCC.
Junior faculty members are eligible to apply for Full Membership if they are planning to conduct cancer research and they apply at the time of Yale appointment with the understanding that these members will meet the eligibility requirements within 3 years of receiving membership. [Full eligibility]
Clinical and Research Membership
Clinical and Research Members are individuals who do not meet the criteria for Full Membership, but who meaningfully contribute to activities of YCC. Clinical Members typically hold a clinical appointment and actively treat patients while Research Members are usually engaged in relevant basic or population science research in cancer. They must be affiliated with the Yale School of Medicine, provide substantive clinical, scientific, administrative, basic, or population expertise to the overall research mission of YCC, and optionally one of the following: 1) Contribute to the peer-reviewed cancer literature; 2) Participate on an extramural cancer-relevant peer-reviewed grant; 3) Contribute to YCC interventional (therapeutic or non-therapeutic) cancer clinical trials.
Research ProgramsYale Cancer Center member candidates select from the following seven thematic Research Programs (RPs) when applying for membership after determining which research program will best support their cancer research efforts. Each RP is led by two Program Leaders (PLs), usually one focused on the basic science aspects of the RP, and the other representing the clinical aspects.
Cancer Immunology (CI)
Lieping Chen, MD, PhD - basic
Mario Sznol, MD - clinical
Cancer Prevention and Control (CPC)
Melinda Irwin, PhD, MPH
Xiaomei Ma, PhD
Developmental Therapeutics (DT)
Karen Anderson, PhD - basic
Barbara Burtness, MD - clinical
Marcus Bosenberg, PhD - basic
Lajos Pusztai, MD, PhD - clinical
Radiobiology and Radiotherapy (RR)
Peter Glazer, MD, PhD - clinical
Joann Sweasy, PhD - basic
Signal Transduction Research Program (ST)
Daniel Petrylak, MD - clinical
David Stern, PhD - basic
Mark Lemmon, PhD - basic
Walther Mothes, PhD - basic
Wendell Yarbrough, MD - clinical